These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 21148494)
21. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects. Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638 [TBL] [Abstract][Full Text] [Related]
22. Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study. Langley JM; Scheifele DW; Quach C; Vanderkooi OG; Ward B; McNeil S; Dobson S; Kellner JD; Kuhn S; Kollman T; MacKinnon-Cameron D; Smith B; Li Y; Halperin SA Vaccine; 2012 May; 30(23):3389-94. PubMed ID: 22469860 [TBL] [Abstract][Full Text] [Related]
23. A population based cohort study to assess the safety of pandemic influenza vaccine Focetria in Emilia-Romagna region, Italy - part two. Moro ML; Nobilio L; Voci C; Di Mario S; Candela S; Magrini N; Vaccine; 2013 Feb; 31(10):1438-46. PubMed ID: 22885015 [TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age. Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G Pediatr Infect Dis J; 2014 Dec; 33(12):e320-9. PubMed ID: 24978857 [TBL] [Abstract][Full Text] [Related]
25. Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine: Two Open-label, Randomized Trials. Vesikari T; Richardus JH; Berglund J; Korhonen T; Flodmark CE; Lindstrand A; Silfverdal SA; Bambure V; Caplanusi A; Dieussaert I; Roy-Ghanta S; Vaughn DW Pediatr Infect Dis J; 2015 Jul; 34(7):774-82. PubMed ID: 26069949 [TBL] [Abstract][Full Text] [Related]
26. A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination. Reisinger KS; Holmes SJ; Pedotti P; Arora AK; Lattanzi M Hum Vaccin Immunother; 2014; 10(8):2395-407. PubMed ID: 25424947 [TBL] [Abstract][Full Text] [Related]
27. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial. Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857 [TBL] [Abstract][Full Text] [Related]
28. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects. Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791 [TBL] [Abstract][Full Text] [Related]
29. A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months. Carmona Martinez A; Salamanca de la Cueva I; Boutet P; Vanden Abeele C; Smolenov I; Devaster JM Hum Vaccin Immunother; 2014; 10(7):1959-68. PubMed ID: 25424805 [TBL] [Abstract][Full Text] [Related]
30. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. Jackson LA; Campbell JD; Frey SE; Edwards KM; Keitel WA; Kotloff KL; Berry AA; Graham I; Atmar RL; Creech CB; Thomsen IP; Patel SM; Gutierrez AF; Anderson EL; El Sahly HM; Hill H; Noah DL; Bellamy AR JAMA; 2015 Jul; 314(3):237-46. PubMed ID: 26197184 [TBL] [Abstract][Full Text] [Related]
31. Immunogenicity of pandemic (H1N1) 2009 vaccine in children with cancer in the United Kingdom. Bate J; Yung CF; Hoschler K; Sheasby L; Morden J; Taj M; Heath PT; Miller E Clin Infect Dis; 2010 Dec; 51(12):e95-104. PubMed ID: 21067352 [TBL] [Abstract][Full Text] [Related]
32. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Manuel O; Pascual M; Hoschler K; Giulieri S; Alves D; Ellefsen K; Bart PA; Venetz JP; Calandra T; Cavassini M Clin Infect Dis; 2011 Jan; 52(2):248-56. PubMed ID: 21288852 [TBL] [Abstract][Full Text] [Related]
33. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. Waddington CS; Walker WT; Oeser C; Reiner A; John T; Wilkins S; Casey M; Eccleston PE; Allen RJ; Okike I; Ladhani S; Sheasby E; Hoschler K; Andrews N; Waight P; Collinson AC; Heath PT; Finn A; Faust SN; Snape MD; Miller E; Pollard AJ BMJ; 2010 May; 340():c2649. PubMed ID: 20508026 [TBL] [Abstract][Full Text] [Related]
34. Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination. Gefenaite G; Tacken M; Bos J; Stirbu-Wagner I; Korevaar JC; Stolk RP; Wolters B; Bijl M; Postma MJ; Wilschut J; Nichol KL; Hak E PLoS One; 2013; 8(6):e66125. PubMed ID: 23840413 [TBL] [Abstract][Full Text] [Related]
36. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Madhun AS; Akselsen PE; Sjursen H; Pedersen G; Svindland S; Nøstbakken JK; Nilsen M; Mohn K; Jul-Larsen A; Smith I; Major D; Wood J; Cox RJ Vaccine; 2010 Dec; 29(2):266-73. PubMed ID: 21034828 [TBL] [Abstract][Full Text] [Related]
37. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age. Nassim C; Christensen S; Henry D; Holmes S; Hohenboken M; Kanesa-Thasan N Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661 [TBL] [Abstract][Full Text] [Related]
38. Immune response after one or two doses of pandemic influenza A (H1N1) monovalent, AS03-adjuvanted vaccine in HIV infected adults. Nielsen AB; Nielsen HS; Nielsen L; Thybo S; Kronborg G Vaccine; 2012 Nov; 30(49):7067-71. PubMed ID: 23036498 [TBL] [Abstract][Full Text] [Related]
39. Safety of AS03-adjuvanted influenza vaccines: A review of the evidence. Cohet C; van der Most R; Bauchau V; Bekkat-Berkani R; Doherty TM; Schuind A; Tavares Da Silva F; Rappuoli R; Garçon N; Innis BL Vaccine; 2019 May; 37(23):3006-3021. PubMed ID: 31031030 [TBL] [Abstract][Full Text] [Related]
40. Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus. Zuccotti GV; Pariani E; Scaramuzza A; Santoro L; Giani E; Macedoni M; Gazzarri A; Anselmi G; Amendola A; Zanetti A Diabet Med; 2011 Dec; 28(12):1530-6. PubMed ID: 21916971 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]